Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19

New Microbes and New Infections

M. Yagisawa¹  D.E. Scheim²  A.D. Santin³  T.J. Borody⁴  P.A. McCullough⁵ 

[1] Corresponding author: David E. Scheim.;Gynecology, Yale University School of Medicine, New Haven, CT, USA;;Department of Obstetrics &;Texas A &US Public Health Service, Inactive Reserve, Blacksburg, VA, USA;

关键词: COVID-19;    H. pylori;    ivermectin;    SARS-CoV-2;    spike protein;   

DOI  :  

来源: DOAJ

【 摘 要 】

In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world’s most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.

【 授权许可】

Unknown